SCHEMBL5524176

SCHEMBL5524176

CC(C)c1ccc(Nc2nccc3cnccc23)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 0.56
SMN1; SMN2 Q16637 5/20 0.47
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
ALDH1A1 P00352 2/20 0.47
POLB P06746 1/20 0.47
HPGD P15428 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NFKB1 P19838 1/20 0.45
TNF P01375 2/20 0.42
DHFR P00374 1/20 0.40
CCNK O75909 1/20 0.40
CDK4 P11802 1/20 0.40
CCNC P24863 1/20 0.40
CDK2 P24941 1/20 0.40
CDK8 P49336 1/20 0.40
GSK3B P49841 1/20 0.40
CDK9 P50750 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5530070 0.78 KDR (0.48) KDRSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL7168182 0.76 ROCK2 (0.38) KDRSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL7168174 0.76 ROCK2 (0.38) KDRSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL16432465 0.76 NPC1 (0.61) SMN1; SMN2NPC1RAB9AALDH1A1POLB
SCHEMBL5264737 0.76 TRPV1 (0.37) KDRSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL5149503 0.76 TRPV1 (0.37) KDRSMN1; SMN2NPC1RAB9AALDH1A1
Hydrochloric Acid SCHEMBL16432037 0.74 NPC1 (0.59) SMN1; SMN2NPC1RAB9AALDH1A1POLB
SCHEMBL38666236 0.74 CDK2 (0.48) KDRCDK2EGFR
SCHEMBL2736702 0.73 LATS1 (0.50) NFKB1LATS1
SCHEMBL15826710 0.72 LATS1 (0.55) LATS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070060582-A1 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases FINK CYNTHIA A 2007-03-15 US disclosed
EP-1667980-A1 1,4-DISUBSTITUTED ISOQUINOLINE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2006-06-14 EP disclosed
WO-2005028444-A1 1,4-DISUBSTITUTED ISOQUINILONE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060582-A1 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases BRAF, RAF1, NRAS KDR 1189/4885SMN1; SMN2 4098/4885NPC1 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.